On July 10, 2018 Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, reported the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President (Press release, Tmunity Therapeutics, JUL 10, 2018, View Source [SID1234527636]). Dr. Coughlin formerly served as Chief Medical Officer at Immunocore Ltd., a British biotechnology company, where she was responsible for leading the effort to develop novel bispecific T cell receptor-based biologics for cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Chris’ depth and breadth of experience in immunotherapeutic clinical development will be tremendously valuable to Tmunity," said Usman "Oz" Azam, MD, President and Chief Executive Officer of Tmunity. "We are fortunate to have her clinical and scientific leadership as we advance our portfolio of next-generation T cell immunotherapies, targeting liquid and solid tumor cancers, through pre-clinical and Phase 1 studies."

​
In her role at Tmunity, Dr. Coughlin will be responsible for clinical development, program leadership and regulatory affairs.

"In addition to her great immunotherapeutic industry knowledge, Chris will also fuse the research and translational capabilities that she developed when she was part of our team at UPenn," said Carl H. June, MD, Director of the Center for Cellular Immunotherapies at the Perleman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.

During her tenure at Immunocore, Dr. Coughlin led the Company’s clinical efforts and developed a pivotal program around the gp100-specific TCR bispecific in uveal melanoma. She previously led early development programs at Novartis, including programs focused on the investigation of checkpoint inhibition and PI3’ kinase inhibition. Dr. Coughlin has both biotechnology and large pharmaceutical industry experience, having held senior medical positions at Morphotek (Eisai), Pfizer and Wyeth.

Earlier in her career, Dr. Coughlin was a physician-scientist at the University of Pennsylvania and the Children’s Hospital of Philadelphia where she studied patient responses to tumor antigens with Dr. Robert Vonderheide in the division of Translational Research under the direction of Dr. June.

Dr. Coughlin holds a Bachelor of Science degree from Temple University and an MD and PhD from the University of Pennsylvania. She completed her residency and a hematology/oncology fellowship at Children’s Hospital of Philadelphia, as well as a research post-doctoral fellowship at the University of Pennsylvania. Dr. Coughlin was also elected a Fellow of the Royal Society of Medicine (London, UK).

On July 10, 2018 Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, announced today that it has entered into a Global License Agreement ("the Agreement") with Novartis Pharma AG, a global pharmaceutical company (Press release, Adlai Nortye Biopharma, JUL 10, 2018, View Source [SID1234556283]). Under the terms of the Agreement, except for certain rights maintained by Novartis Pharma AG, Adlai Nortye will have exclusive development and commercialization rights to buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Buparlisib (BKM120) is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms and is active in both hematologic malignancies and solid tumors. It has shown promising efficacy in combination with paclitaxel in head and neck squamous cell carcinoma (HNSCC) and has received a Fast-Track designation from the FDA.

"Combination of buparlisib and paclitaxel demonstrated improved clinical efficacy with a manageable safety profile in patients with HNSCC compared to paclitaxel alone," said Dr. Lars Birgerson, Chief Development Officer of Adlai Nortye and President & CEO of Adlai Nortye USA Inc. "We believe that buparlisib will be another key component in furthering development of our oncology pipeline, and it has great potential for future application in cancer treatment."

"Buparlisib has been extensively profiled in breast cancer and other tumor types. Buparlisib when combined with other therapies has shown impressive anti-cancer efficacy in HNSCC," said Carsten Lu, CEO of Adlai Nortye, "It has very good market prospects when combined with paclitaxel, and we are planning to carry out clinical trials of combination of buparlisib and immune check point inhibitor treatment."

On July 10, 2018 Illumina, Inc. (NASDAQ:ILMN) reported that it will issue results for second quarter 2018 following the close of market on Monday, July 30, 2018 (Press release, Illumina, JUL 10, 2018, View Source [SID1234527637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Monday, July 30, 2018. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the "company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing 800-708-4539, or 1-847-619-6396 outside North America, both with passcode 47172781.

A replay of the conference call will be available from 4:30 pm Pacific Time (7:30 pm Eastern Time) on July 30, 2018 through August 6, 2018 by dialing 888-843-7419, or 1-630-652-3042 outside North America, both with passcode 47172781.

On July 10, 2018 Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, reported that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunity for new combination approaches in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) from 8:30-10:30 a.m. ET on Tuesday, July 17, 2018 in New York City (Press release, Syros Pharmaceuticals, JUL 10, 2018, View Source [SID1234527702]). Syros is currently evaluating SY-1425, its first-in-class, selective retinoic acid receptor alpha (RARα) agonist, in a Phase 2 clinical trial in combination with standard-of-care and targeted therapies in genomically defined subsets of AML and MDS patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations from Rachel J. Cook, M.D., M.S., Assistant Professor of Medicine and Site Director for Acute Leukemia at the Knight Cancer Institute, Oregon Health and Science University and Eytan M. Stein, M.D., Assistant Professor of Medicine; Leukemia Service, Department of Medicine at Memorial Sloan Kettering Cancer Center. Additionally, members of Syros’ management will provide an overview of SY-1425 and review preclinical and clinical data supporting its combination strategy with SY-1425.

A live webcast of the event will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following each presentation.

On July 9, 2018 Syntimmune, Inc., a clinical-stage biotechnology company developing antibody therapeutics targeting FcRn, reported the appointment of biopharma executive Mario Saltarelli, M.D., Ph.D., as chief medical officer (Press release, Syntimmune, JUL 9, 2018, View Source [SID1234527619]).

Dr. Saltarelli, who most recently served as senior vice president at Vertex, brings broad experience in discovery research, clinical development, pipeline strategy and global regulatory operations. Dr. Donald Johns, who has been acting chief medical officer, will become the executive vice president of medical and scientific affairs for Syntimmune."Mario’s deep expertise in drug development and strong leadership skills will be a tremendous asset to Syntimmune as we advance our pipeline of novel therapies targeting a broad range of autoimmune diseases," said Jean-Paul Kress, M.D., Syntimmune’s president and CEO. "We’re thrilled to have him on board to lead our medical organization. I’d also like to thank Don for his support as acting CMO, and I’m pleased that he’ll be continuing to help Syntimmune strengthen our medical and scientific leadership position."Dr. Saltarelli comes to Syntimmune from Vertex, where he managed clinical development projects across multiple therapeutic areas as senior vice president, early development and neurology. At Vertex, he supported the NDA/MAA preparation and filing of Symdeko (tezacaftor/ivacaftor), leading to FDA approval. He also advanced multiple early development assets. Prior to Vertex, Dr. Saltarelli served as chief medical officer of Annexion Biosciences and as senior vice president and chief science officer at Mallinckrodt Pharmaceuticals. Dr. Saltarelli has also held leadership roles at Shire, Abbott (AbbVie) and Pfizer. Throughout his career, Dr. Saltarelli has worked on the full range of pharmaceutical research and development needs, including translational sciences, clinical strategy, pharmacology and medical affairs. Dr. Saltarelli earned both an M.D. and a Ph.D. in neurosciences from Johns Hopkins University School of Medicine.

"This is an exciting moment for Syntimmune, with multiple clinical trials underway and planned, and I am delighted to be able to contribute," Dr. Saltarelli said. "Syntimmune has a strong vision of leveraging its unique insights into FcRn, honed over 25 years of research, to develop novel therapies that will truly help patients. I’m honored to be part of the team."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Johns is an accomplished drug development leader with extensive experience in drug discovery and development. He is a board-certified clinical neurologist and scientific leader with 25+ years of experience in rare and orphan diseases. Prior to joining Syntimmune, Dr. Johns held leadership positions at Biogen, Novartis Institutes for BioMedical Research, the Center for the Integration of Medicine and Innovative Technology and Beth Israel Deaconess Medical Center. He contributed to three successful New Drug Applications (EXELON PATCH: Alzheimer Disease, GILENYA: Relapsing Remitting Multiple Sclerosis, SPINRAZA: Spinal Muscular Atrophy). He is the founding principal of Axon Guidance LLC, a neuroscience-focused drug development consultancy. He has also held teaching positions at Harvard Medical School and Johns Hopkins University School of Medicine. Dr. Johns received his M.D. from the Yale University School of Medicine. He completed his Neurology residency and fellowship at Massachusetts General Hospital.